Kane Biotech (CVE:KNE) Shares Down 13% – What’s Next?

Kane Biotech Inc. (CVE:KNE) shares traded down 13% on Monday . The company traded as low as C$0.10 and last traded at C$0.10. 235,000 shares traded hands during mid-day trading, an increase of 90% from the average session volume of 123,822 shares. The stock had previously closed at C$0.12.

Kane Biotech Trading Down 13.0 %

The company has a current ratio of 0.82, a quick ratio of 0.39 and a debt-to-equity ratio of 1,164.24. The company has a 50-day moving average price of C$0.12 and a two-hundred day moving average price of C$0.13. The stock has a market cap of C$13.25 million, a P/E ratio of -3.83 and a beta of 0.52.

Kane Biotech Company Profile

Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections.